US 9,314,520 B2 · Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles

Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles

AssigneesBioleaders Corporation, Kookmin University Industry-Academic Cooperation Foundation, Korea Research Institute of Bioscience and Biotechnology, The Industry & Academic Cooperation in Chungnam National University, Chungbuk National University Industry Academic Cooperation

InventorsMoon-Hee Sung, Haryoung Poo, Chul Joong Kim, Young-Ki Choi, Yong Taik Lim, Dong Jin Jeong, Sang-Mu Shim

Life of this patent

Estimating the term…

Abstract

The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.

Claims5

Dependent claims

A method of increasing production of an antibody against an antigen in an animal, the method comprising:

administering a composition comprising a complex molecule to an animal,
the complex molecule comprising a negatively charged antigen, protonated chitosan, and poly-gamma glutamic acid,
wherein the negatively charged antigen and the poly-gamma glutamic acid are electrostatically bound to the protonated chitosan to form the complex molecule,
wherein the poly-gamma glutamic acid is included in the complex molecule in an amount sufficient to make the complex molecule negatively charged on its outer surface.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

13/380,503Filed 25 Jun 2010

Priority

KR 10-2009-005684425 Jun 2009

Published

US 2012/0164174 A128 Jun 2012

Granted

19 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/145
Viral antigens: orthomyxoviridae, e.g. influenza virus
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents